Table 2:
Patients/Grades | No. | CBFmax (mL/100 g/min) |
rCBFmax | |
---|---|---|---|---|
Tumor | Contralateral | |||
All | ||||
Grade II | 13 | 85.8 ± 30.3 | 85.3 ± 16.4 | 1.03 ± 0.41 |
Grade III | 17 | 146.4 ± 84.0b | 80.0 ± 16.1 | 1.81 ± 0.96c |
Grade IV | 28 | 171.5 ± 58.7d | 77.0 ± 10.9 | 2.25 ± 0.15d |
Excludeda | ||||
Grade II | 9 | 75.1 ± 10.4 | 87.7 ± 18.6 | 0.88 ± 0.16 |
Grade III | 13 | 126.1 ± 74.7e | 80.4 ± 16.6 | 1.52 ± 0.77b |
Grade IV | 28 | 171.5 ± 58.7d,f | 77.0 ± 10.9 | 2.25 ± 0.15d,g |
With oligodendrogliomas and anaplastic oligodendrogliomas excluded. Note the following P values in each patient group:
P < .05, compared with grade II.
P < .01, compared with grade II.
P < .001, compared with grade II.
P = .05, compared with grade II.
P < .05, compared with grade III.
P < .01, compared with grade III.